HR Execs on the Move

Sage Recovery & Wellness Center

www.sagerecoveryaustin.com

 
Sage Recovery & Wellness Center Austin is an outpatient center specializing in both mental health and substance use, utilizing a holistic approach to recovery.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Cumberland Pharmaceuticals

Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. With a focus on underserved niche markets, including hospital acute care and gastroenterology, we deliver products that serve patients in the U.S. market. Cumberland also makes its products available to patients internationally through select strategic partnerships. We own the worldwide rights to all our brands. While Cumberland`s commercial capabilities are focused on the U.S. market, our business development team is actively pursuing opportunities to make our brands available to patients in markets around the globe. Our primary mission is to improve upon patient care with products that offer clear advantages over existing treatments. We also strive to deliver solutions that may help reduce costs for healthcare providers and, ultimately, patients.

Rising Pharmaceuticals

Rising Pharmaceuticals is an industry leader in marketing and distributing innovative branded and multi-source prescription and over-the-counter pharmaceutical products.

Acro Pharmaceutical Services

Acro Pharmaceutical Services is a Sharon Hill, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Smile Workshop

Smile Workshop is dedicated in giving families the services they really care about from their dentist. Pediatrics and accepting Medicaid!

Oramed

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).